[28] Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients[J]. Breast Cancer Res Treat, 2014, 147(2):401-405. doi: 10.1007/s10549-01...
[4]Akkoc Mustafayev FN, Shukla MA, Lanier A, et al. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer. 2024 May 1;130(9):1600-1608. 审批编号：CN-148467 有效期至：2025-11-27 本材料由阿斯利康提供，仅供医疗卫生专业人士参考 （转自...
参考来源: 1.Byrski T, Huzarski T, Dent R, et al:Pathologic complete response to neoadjuvant cisplatin inBRCA1 positive breast cancer patients. Breast Cancer Res Treat 147:401-5, 2014 2.KaufmanB,ShapiraFrommer R, Schmutzler RK, et al:...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial...
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast CancersWayne Kuznar
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005;18(10):1321–8.Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18:1321-8....
Clinical and Pathological Characteristics of BRCA2 Positive Breast Cancer in Egyptian Female PatientsClinical and Pathological Characteristics of BRCA2 Positive Breast Cancer in Egyptian Female PatientsMutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. Early age at ons...
Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. Oncologist 2012; 17: 1409-1417 [PMID: 23006497 DOI: 10.1634/theoncologist.2012-0236]A. Kenny, Rodriguez-Wallberg, Kutluk Oktay. Fertility preservation and pregnancy in women with and without BRCA ...
we had a publication in the New England Journal of Medicine of the results of the EMBER-3 trial investigated an oral SERD called Imlunestrant in the management of patients with Hormone receptor-positive , HER2 negative, advanced breast cancer with endocrine-resistant disease. And in this trial...
we had a publication in the New England Journal of Medicine of the results of the EMBER-3 trial investigated an oral SERD called Imlunestrant in the management of patients with Hormone receptor-positive,HER2 negative,advanced breast cancer with endocrine-resistant disease.And in this trial,the ...